IPSEN – Buy-back programme – Art 5 of MAR – Week 49- 2025
| Aggregated presentation by day and by market
Statement of transactions in own shares from December 1st to December 05th 2025 |
||||||
| Name of the issue | Identity code of the issuer (Legal Entity Identifier) |
Day of the transaction | Identity code of the financial instrument | Total daily volume (in number of shares) | Daily weighted average purchase price of the shares | Market (MIC Code) |
| IPSEN | 549300M6SGDPB4Z94P11 | 01/12/2025 | FR0010259150 | 200 | 124,05000 | AQEU |
| IPSEN | 549300M6SGDPB4Z94P11 | 01/12/2025 | FR0010259150 | 831 | 123,81540 | CEUX |
| IPSEN | 549300M6SGDPB4Z94P11 | 01/12/2025 | FR0010259150 | 100 | 124,40000 | TQEX |
| IPSEN | 549300M6SGDPB4Z94P11 | 01/12/2025 | FR0010259150 | 1897 | 124,16958 | XPAR |
| 3028 | 124,07209 | |||||
Attachment
IPSEN – Buy-back programme – Art 5 of MAR – Week 49- 2025
| Aggregated presentation by day and by market
Statement of transactions in own shares from December 1st to December 05th 2025 |
||||||
| Name of the issue | Identity code of the issuer (Legal Entity Identifier) |
Day of the transaction | Identity code of the financial instrument | Total daily volume (in number of shares) | Daily weighted average purchase price of the shares | Market (MIC Code) |
| IPSEN | 549300M6SGDPB4Z94P11 | 01/12/2025 | FR0010259150 | 200 | 124,05000 | AQEU |
| IPSEN | 549300M6SGDPB4Z94P11 | 01/12/2025 | FR0010259150 | 831 | 123,81540 | CEUX |
| IPSEN | 549300M6SGDPB4Z94P11 | 01/12/2025 | FR0010259150 | 100 | 124,40000 | TQEX |
| IPSEN | 549300M6SGDPB4Z94P11 | 01/12/2025 | FR0010259150 | 1897 | 124,16958 | XPAR |
| 3028 | 124,07209 | |||||
Attachment
Related Press Releases
Ojemda® approved in the European Union as the first targeted...
Ipsen announces that Beech Tree has obtained an exemption from...
Ipsen announces the availability of its 2025 Universal Registration Document
Ipsen – February 2026 – Monthly information relative to the...
Ipsen appoints Michelle C. Werner as EVP, President of North...
Ipsen S.A. publishes its 2025 Consolidated Financial Statements
Ipsen – January 2026 – Monthly information relative to the...
Ipsen nominates Peter Guenter to its Board of Directors
Arbitration tribunal upholds Ipsen’s termination of R&D agreement with Galderma
Ipsen – December 2025 – Monthly information relative to the...